Adding Ipilimumab to Nivolumab Doesn’t Provide Meaningful Benefit, Researchers Say
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.
Cancer patients were more likely to die from the BA.1 and BA.2 omicron variants of SARS-CoV-2 than from wild-type SARS-CoV-2, data suggest.
The burden of administrative tasks required to pay for cancer care is associated with nonadherence to care, a new study suggests.
Cancer death rates have declined in the United States in recent years, but the declines are greater in urban than in rural areas, data suggest.
Meta-analysis only shows a 110-day survival benefit for colorectal cancer screening with sigmoidoscopy
Deaths in patients with COVID-19 and cancer made up 81% of excess deaths among cancer patients during the first 2 years of the pandemic.
Black and Hispanic patients have a higher risk of death from second primary cancers than White and Asian/Pacific Islander patients, new data suggest.
Cancer patients may be particularly susceptible to transportation-related disruptions in care.
The main cause of the cancer drug shortage, experts agree, is the underlying weakness of the generic drug industry.
Malnutrition may affect 30% to 85% of cancer patients, and it may account for 10% to 20% of deaths in these patients.